ANP 8.57% 9.6¢ antisense therapeutics limited

Extract from June 2002 Update

  1. 280 Posts.
    Pleased to report that Antisense Therapeutics Limited has made substantial progress since the March 2002 Investor Update. All R & D activities are on track with several significant advances in our drug development pipeline as detailed below.

    Preclinical dosing studies have been completed on ATLl102 for Multiple Sclerosis. Detailed toxicology and pharmacokinetic analysis is underway with the results
    expected in 4Q 2002. Identification of the site for conduct of Phase I human clinical trials is close to finalisation with the study on track to commence in early 03.

    Selection of ths ATL1101 Psoriasis lead compound is on track for 3Q 2002 following the successful completion of several key experiments using human skin cells at the
    Murdoch Childrens Research Institute (MCM).

    Five new antisense lead compounds have been produced by Isis Pharmaceuticals Inc (Isis) designed to treat large disease markets involving viral, skin, growth and inflammatory disorders.

    The rapid progress in ATL1102 drug development, and in ATL11O1 and pipeline research since the last update is a clear illustration of the remarkable speed with which
    antisense drugs can be discovered and moved into clinical development compared to traditional approaches.

    With a heavy sell-down, and currently at 13c, I feel they only have one way to go........UP.


watchlist Created with Sketch. Add ANP (ASX) to my watchlist
(20min delay)
Mkt cap ! $64.20M
Open High Low Value Volume
10.5¢ 10.5¢ 9.6¢ $144.7K 1.431M

Buyers (Bids)

No. Vol. Price($)
1 10199 9.6¢

Sellers (Offers)

Price($) Vol. No.
11.0¢ 715120 6
View Market Depth
Last trade - 16.10pm 20/05/2022 (20 minute delay) ?
-0.009 ( 6.67 %)
Open High Low Volume
10.0¢ 10.5¢ 9.8¢ 429608
Last updated 15.58pm 20/05/2022 (live) ?
ANP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.